Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sean Wasserman

Showing results (101-110 of 111) with videos related to

Pageof 12
Sort By:
The Lancet. Respiratory Medicine|October 13, 2022
Colchicine and aspirin in community patients with COVID-19 (ACT): an open-label, factorial, randomised, controlled trialJohn W Eikelboom, Sanjit S Jolly, Emilie P Belley-Cote, et al.
Wellcome Open Research|July 21, 2021
Study protocol for a phase 2A trial of the safety and tolerability of increased dose rifampicin and adjunctive linezolid, with or without aspirin, for HIV-associated tuberculous meningitis [LASER-TBM]Angharad G Davis, Sean Wasserman, Mpumi Maxebengula, et al.
BMC Infectious Diseases|June 20, 2022
Clinical features and outcomes of COVID-19 admissions in a population with a high prevalence of HIV and tuberculosis: a multicentre cohort studyArifa Parker, Linda Boloko, Muhammad S Moolla, et al.
CJC Open|March 7, 2022
The Anti-Coronavirus Therapies (ACT) Trials: Design, Baseline Characteristics, and ChallengesJohn Eikelboom, Sumathy Rangarajan, Sanjit S Jolly, et al.
The Lancet. Infectious Diseases|September 29, 2024
Advancing the chemotherapy of tuberculous meningitis: a consensus viewSean Wasserman, Joseph Donovan, Evelyne Kestelyn, et al.
The New England Journal of Medicine|January 29, 2025
Oral Regimens for Rifampin-Resistant, Fluoroquinolone-Susceptible TuberculosisLorenzo Guglielmetti, Uzma Khan, Gustavo E Velásquez, et al.
Tropical Medicine & International Health : TM & IH|April 12, 2022
Outcomes of laboratory-confirmed SARS-CoV-2 infection in the Omicron-driven fourth wave compared with previous waves in the Western Cape Province, South AfricaMary-Ann Davies, Reshma Kassanjee, Petro Rousseau, et al.
Medrxiv : the Preprint Server for Health Sciences|January 19, 2022
Outcomes of laboratory-confirmed SARS-CoV-2 infection in the Omicron-driven fourth wave compared with previous waves in the Western Cape Province, South AfricaMary-Ann Davies, Reshma Kassanjee, Petro Rosseau, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|November 27, 2022
Outcomes of laboratory-confirmed SARS-CoV-2 infection during resurgence driven by Omicron lineages BA.4 and BA.5 compared with previous waves in the Western Cape Province, South AfricaMary-Ann Davies, Erna Morden, Petro Rousseau, et al.
Medrxiv : the Preprint Server for Health Sciences|July 7, 2022
Outcomes of laboratory-confirmed SARS-CoV-2 infection during resurgence driven by Omicron lineages BA.4 and BA.5 compared with previous waves in the Western Cape Province, South AfricaMary-Ann Davies, Erna Morden, Petro Rosseau, et al.
Pageof 12

Showing results (101-110 of 111) with videos related to

Sort By:
Pageof 12
The Lancet. Respiratory Medicine|October 13, 2022
Colchicine and aspirin in community patients with COVID-19 (ACT): an open-label, factorial, randomised, controlled trialJohn W Eikelboom, Sanjit S Jolly, Emilie P Belley-Cote, et al.
Wellcome Open Research|July 21, 2021
Study protocol for a phase 2A trial of the safety and tolerability of increased dose rifampicin and adjunctive linezolid, with or without aspirin, for HIV-associated tuberculous meningitis [LASER-TBM]Angharad G Davis, Sean Wasserman, Mpumi Maxebengula, et al.
BMC Infectious Diseases|June 20, 2022
Clinical features and outcomes of COVID-19 admissions in a population with a high prevalence of HIV and tuberculosis: a multicentre cohort studyArifa Parker, Linda Boloko, Muhammad S Moolla, et al.
CJC Open|March 7, 2022
The Anti-Coronavirus Therapies (ACT) Trials: Design, Baseline Characteristics, and ChallengesJohn Eikelboom, Sumathy Rangarajan, Sanjit S Jolly, et al.
The Lancet. Infectious Diseases|September 29, 2024
Advancing the chemotherapy of tuberculous meningitis: a consensus viewSean Wasserman, Joseph Donovan, Evelyne Kestelyn, et al.
The New England Journal of Medicine|January 29, 2025
Oral Regimens for Rifampin-Resistant, Fluoroquinolone-Susceptible TuberculosisLorenzo Guglielmetti, Uzma Khan, Gustavo E Velásquez, et al.
Tropical Medicine & International Health : TM & IH|April 12, 2022
Outcomes of laboratory-confirmed SARS-CoV-2 infection in the Omicron-driven fourth wave compared with previous waves in the Western Cape Province, South AfricaMary-Ann Davies, Reshma Kassanjee, Petro Rousseau, et al.
Medrxiv : the Preprint Server for Health Sciences|January 19, 2022
Outcomes of laboratory-confirmed SARS-CoV-2 infection in the Omicron-driven fourth wave compared with previous waves in the Western Cape Province, South AfricaMary-Ann Davies, Reshma Kassanjee, Petro Rosseau, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|November 27, 2022
Outcomes of laboratory-confirmed SARS-CoV-2 infection during resurgence driven by Omicron lineages BA.4 and BA.5 compared with previous waves in the Western Cape Province, South AfricaMary-Ann Davies, Erna Morden, Petro Rousseau, et al.
Medrxiv : the Preprint Server for Health Sciences|July 7, 2022
Outcomes of laboratory-confirmed SARS-CoV-2 infection during resurgence driven by Omicron lineages BA.4 and BA.5 compared with previous waves in the Western Cape Province, South AfricaMary-Ann Davies, Erna Morden, Petro Rosseau, et al.
Pageof 12